In this video, Motley Fool Health-Care Analyst David Williamson breaks down just what happened in the recent Canadian Supreme Court ruling against Pfizer (NYSE:PFE). The Canadian patent on the company's drug Viagra was due to expire in 2014, but the Court struck down the patent in a unanimous ruling, invalidating the patent. Williamson explains the losers and the winners in this situation, and just how much we can expect Pfizer to really be affected.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.